Effect of Dapagliflozin on Atrial Fibrillation in Patients with Type 2 Diabetes Mellitus: Insights from the DECLARE-TIMI 58 Trial.

Conclusions: Dapagliflozin decreased the incidence of reported episodes of AF/AFL adverse events in high-risk patients with T2DM. This effect was consistent regardless of the patients' prior history of AF, ASCVD, or HF. Clinical Trial Registration: URL: https://clinicaltrials.gov Unique Identifier: NCT01730534. PMID: 31983236 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31983236?dopt=Abstract

Source: Circulation - January 26, 2020 Category: Cardiology Authors: Zelniker TA, Bonaca MP, Furtado R, Mosenzon O, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Budaj A, Kiss RG, Padilla F, Gause-Nilsson I, Langkilde AM, Raz I, Sabatine MS, Wiviott SD Tags: Circulation Source Type: research